Palantir Stock Soars as AI Demand Drives Strong Q2 Earnings and Higher 2026 Outlook 
Trump Urges Exxon, Chevron to Cut Gas Prices After Record Oil Profits 
Siemens Energy Q3 Profit Beats Forecast as AI-Driven Power Demand Fuels Growth 
Meta AI Model Exploits Security Flaw During Cybersecurity Test, Raising AI Safety Concerns 
DHL Q2 Profit Jumps 24% as Express Business Drives Growth 
Bayer Q2 Earnings Beat Forecasts as Crop Science Boosts Results, Debt Outlook Improves 
Glencore Posts Strong H1 2026 Earnings, Announces ASX Secondary Listing 
SpaceX Targets Starship Flight 14 With First V3 Starlink Satellite Launch 
FleetPartners Shares Jump After A$760 Million Takeover Proposal From Pacific Equity Partners 
Infineon Raises 2026 Revenue Outlook as AI Data Center Demand Fuels Record Quarterly Sales 
Novo Nordisk Raises 2025 Outlook Despite Wegovy Pill Miss and CagriSema Setback 
Samsung, SK Hynix Test AMEC Chipmaking Tools for China Backup Plan 
Vast Eyes Hong Kong IPO as Chinese AI Unicorn Gains Momentum 
SK Hynix Bonus Dispute Deepens as Union Rejects Stock-Based Payout Proposal 
Heineken H1 Operating Profit Meets Forecast as Beer Volumes Beat Expectations 
Novo Nordisk Eyes Turnaround as Oral Wegovy Challenges Eli Lilly in Weight-Loss Drug Race 
Shein Targets $30B-$40B Valuation in Hong Kong IPO Planned for August 
GAITHERSBURG, Md., March 22, 2018 -- Altimmune, Inc. (Nasdaq:ALT), a clinical-stage immunotherapeutics company, announced today that Bill Enright, President and Chief Executive Officer, will provide a corporate overview at H.C. Wainwright Global Life Sciences Conference, being held April 8-10 in Monte Carlo, Monaco.
| Presentation Details - H.C. Wainwright Global Life Sciences Conference | ||
| Date: | Tuesday, April 10, 2018 | |
| Time: | 9:25am Eastern Time/3:25pm Central European Time | |
| Location: | LeMeridien Beach Plaza Hotel, Monte Carlo, Salon Atlantique-Meridional | |
| Webcast: | http://wsw.com/webcast/hcw2/alt/ | |
About Altimmune
Altimmune is a clinical-stage immunotherapeutics company focused on the development of products to stimulate robust and durable immune responses for the prevention and treatment of disease including NasoVAX, a Phase 2 seasonal influenza vaccine candidate, and HepTcell, a Phase 1 immunotherapeutic candidate for the potential cure of chronic hepatitis B. The company also has two United States government funded, next-generation anthrax vaccine candidates that are intended to improve protection and safety while having favorable dosage and storage requirements compared to other anthrax vaccines.
Contacts:
Bill Enright
President and CEO
Phone: 240-654-1450
[email protected]
Ashley Robinson
LifeSci Advisors, LLC
617-535-7742
[email protected]
